Three fragment sequential decay of heavy nuclei around 3 MeV/u excitation energy

A new method is proposed to identify the sequential decay of hot nuclei into large fragments. This method is based on a minimization procedure. It is illustrated for the Ar+Au reaction at 30 MeV/u. In this case, corresponding to about 3 MeV/u excitation energy, it is shown that the three fragment production can be explained by sequential binary splittings.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Decay of equilibrated very hot nuclei via multifragment emission

International audienceCoïncidences between at least 3 fragments emitted at large angle have been used to study central collisions in the Ar+Au reactions at 30 and 60 MeV/u incident energies. For both energies, the formation of equilibrated very hot nuclei is evidenced. Excitation energy as high as 1 GeV are reached in the reaction at 60 MeV/u

Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers

International audienceThis phase I, pilot clinical study was designed to evaluate the safety and the pharmacokinetic (PK) profiles of the CIME (Metabolic Identity Card) combination of ten drugs, with a view to its use as a phenotyping cocktail. Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19, dextromethorphan-CYP2D6, midazolam-CYP3A, acetaminophen-UGT1A1, 6&9 and 2B15, digoxin-P-gp, rosuvastatin-OATP1B1&3 and memantine-active renal transport). Blood was collected over 3 days and on day 7. CIME probes and relevant metabolites were assayed by LC-MS/MS and PK parameters were calculated. Main results were: (1) good safety with reversible mild or moderate adverse effects, (2) an analytical method able to quantify simultaneously the 10 probes and the major metabolites, (3) calculation of PK parameters for all probes in general agreed with published values, and (4) identification of the low CYP2D6 metabolizer. This pilot study showed that the CIME combination was well tolerated and that its pharmacokinetics could be accurately measured in healthy volunteers. This combination can now confidently be checked for sensitivity and specificity and for lack of interaction to be validated as a phenotyping cocktail